Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P35052

UPID:
GPC1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P35052; B3KTD1; Q53QM4

BACKGROUND:
Glypican-1 functions as a critical mediator in cell communication and tissue organization. It interacts with collagen and prion proteins through its heparan sulfate chains, facilitating important cellular processes. Additionally, it regulates FGF-mediated signaling, essential for proper muscle development, by trapping FGF2 in lipid rafts, thus preventing its interaction with receptors.

THERAPEUTIC SIGNIFICANCE:
Exploring Glypican-1's mechanisms offers a promising pathway for drug discovery. Its pivotal role in cellular processes and disease pathways, such as prion disease progression and muscle development, highlights its potential as a target for therapeutic intervention. Leveraging Glypican-1's functions could lead to breakthrough treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.